Lipoic Acid Derivative Formulation Targeting Warburg Effect
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer chemotherapy lacks effective targets for cancer cells' altered energy metabolism, particularly the Warburg Effect, which is a fundamental change in cancer cells' energy production, leading to an urgent need for new approaches in disease management.
Innovation Solution
A pharmaceutical formulation comprising lipoic acid derivatives or their salts, combined with an ion pairing agent and optionally a pharmaceutically acceptable diluent, specifically designed to target and kill tumor cells by altering cancer cell metabolism and signal transduction pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy approaches are used, then cancer treatment is attempted, but the treatment lacks effective targets for cancer cells' altered energy metabolism (Warburg Effect)
Solution Approach 1:
The invention changes the chemical parameter of lipoic acid by converting it to its disulfide form (lipoic acid disulfide) or creating derivatives, which alters its metabolic fate in cancer cells. This parameter change enables the compound to be converted by PDC into toxic metabolites that specifically target cancer cells' altered metabolism, resolving the contradiction between treatment effectiveness and ability to target Warburg Effect
Solution Approach 2:
The invention uses pyruvate dehydrogenase (PDC) as an intermediary enzyme that is overexpressed in cancer cells. The lipoic acid disulfide acts as a prodrug that is converted by PDC into toxic metabolites. This intermediary approach allows selective targeting of cancer cells that have elevated PDC activity due to the Warburg Effect, while normal cells with lower PDC activity are spared
2Reliability
If lipoic acid is administered to target cancer cell metabolism, then cancer cell death is induced, but the formulation and delivery method must be optimized for efficacy
Solution Approach 1:
The invention uses a simple pharmaceutical formulation comprising lipoic acid disulfide or derivatives combined with common excipients such as polyethylene glycol, polysorbate, and saline. This simple, disposable formulation approach avoids complex manufacturing processes while achieving reliable cancer cell killing through the metabolic trap mechanism
Solution Approach 2:
The invention changes the chemical parameter of lipoic acid to its disulfide form, which prevents premature reduction and allows stable formulation. This parameter change enables the compound to be stored and administered effectively, resolving the formulation complexity issue while maintaining apoptotic induction capability
3Reliability
If lipoic acid acts as a cofactor with PDC to detoxify metabolites, then cancer cell survival is supported, but inhibiting PDC function is needed to kill cancer cells
Solution Approach 1:
The invention converts the harmful accumulation of toxic metabolites into a beneficial killing mechanism. By administering lipoic acid disulfide that is converted by PDC into toxic metabolites, the invention exploits the Warburg Effect and elevated PDC activity in cancer cells to generate lethal amounts of toxic metabolites, turning what would normally be a detoxification pathway into a cell-killing mechanism
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation effectively inhibits or induces apoptosis in cancer cells while minimizing harm to normal cells, offering a new approach for treating cancers by exploiting the metabolic differences between cancer and normal cells.
Implementation Method 1
The present invention is directed to pharmaceutical formulations containing lipoic acid derivatives or salts thereof which selectively kill tumor cells by altering cancer cell metabolism and signal transduction pathways linked to the Warburg Effect
Implementation Method 2
A pharmaceutical formulation comprising lipoic acid derivatives or their salts, combined with an ion pairing agent and optionally a pharmaceutically acceptable diluent
Data Source
AI summary
The invention provides a method of treating leukemia using a pharmaceutical composition containing bis-benzyl lipoate, triethanolamine, and a pharmaceutically acceptable diluent, where the bis-benzyl lipoate and triethanolamine form an ion pair.